Chilcott, III Thomas E. 4
4 · THERALINK TECHNOLOGIES, INC. · Filed Sep 21, 2022
Insider Transaction Report
Form 4
Chilcott, III Thomas E.
Chief Financial Officer
Transactions
- Award
Stock Option (right to buy)
2022-09-16+94,545,096→ 94,545,096 totalExercise: $0.00Exp: 2032-09-16→ Common Stock (94,545,096 underlying)
Footnotes (1)
- [F1]37,818,039 of the stock options will become exercisable upon the filing by the corporation of an S-8 registration statement covering its 2022 Equity Incentive Plan. The remaining 56,727,058 stock options will vest equally on September 1, 2023, September 1 2024, and September 1, 2025.